881012-64-2

Basic information

• Product Name: Methanesulfonic acid (1S,2S,3R)-2-(4-benzyloxycarbonylamino-phenyl)-3-methanesulfonyloxymethyl-cyclopropylmethyl ester
• Synonyms: Methanesulfonic acid (1S,2S,3R)-2-(4-benzyloxycarbonylamino-phenyl)-3-methanesulfonyloxymethyl-cyclopropylmethyl ester
• CAS NO: 881012-64-2
• Molecular Weight: 483.563
• Mol File: 881012-64-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid (1S,2S,3R)-2-(4-benzyloxycarbonylamino-phenyl)-3-methanesulfonyloxymethyl-cyclopropylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid (1S,2S,3R)-2-(4-benzyloxycarbonylamino-phenyl)-3-methanesulfonyloxymethyl-cyclopropylmethyl ester(881012-64-2)
• EPA Substance Registry System: Methanesulfonic acid (1S,2S,3R)-2-(4-benzyloxycarbonylamino-phenyl)-3-methanesulfonyloxymethyl-cyclopropylmethyl ester(881012-64-2)

Safety Data

• Hazardous Substances Data: 881012-64-2(Hazardous Substances Data)

Upstream product

• 92159-87-0 benzyl (4-bromophenyl)carbamate 
• 71150-68-0 benzyl N-(4-formylphenyl)carbamate 
• 777089-59-5 (2E)-3-{4-[((benzyloxy)carbonyl)amino]phenyl}prop-2-enyl diazoacetate 
• 777089-58-4 benzyl 4-[(1E)-3-hydroxyprop-1-enyl]phenylcarbamate 
• 777089-57-3 methyl (2E)-3-(4-{[(benzyloxy)carbonyl]amino}phenyl)acrylate 
• 777089-61-9 [4-((1S,2R,3S)-2,3-Bis-hydroxymethyl-cyclopropyl)-phenyl]-carbamic acid benzyl ester 
• 7143-01-3 Methanesulfonic anhydride 

Downstream Products

• 777089-64-2 {4-[(1S,5R,6S)-3-(4-Methoxy-benzyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-carbamic acid benzyl ester 
• 777089-67-5 [(1S,5R,6S)-4-(3-Thia-bicyclo[3.1.0]hex-6-yl)-phenyl]-carbamic acid benzyl ester 

Relevant articles and documents

Conformational constraint in oxazolidinone antibacterials. Part 2: Synthesis and structure-activity studies of oxa-, aza-, and thiabicyclo[3.1.0] hexylphenyl oxazolidinones

A new class of oxazolidinone antibacterials incorporating oxygen-, nitrogen-, or sulfur-containing heterobicyclic C-rings is described. The in vitro potency and in vivo efficacy of these conformationally constrained oxazolidinone analogs are discussed.